Pliant Therapeutics (PLRX) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.
- Pliant Therapeutics' Income from Continuing Operations rose 5446.74% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.5 million, marking a year-over-year increase of 1298.19%. This contributed to the annual value of -$210.3 million for FY2024, which is 3035.16% down from last year.
- Latest data reveals that Pliant Therapeutics reported Income from Continuing Operations of -$26.3 million as of Q3 2025, which was up 5446.74% from -$43.3 million recorded in Q2 2025.
- In the past 5 years, Pliant Therapeutics' Income from Continuing Operations registered a high of -$22.8 million during Q2 2021, and its lowest value of -$57.8 million during Q3 2024.
- Over the past 5 years, Pliant Therapeutics' median Income from Continuing Operations value was -$37.5 million (recorded in 2023), while the average stood at -$37.8 million.
- As far as peak fluctuations go, Pliant Therapeutics' Income from Continuing Operations tumbled by 30723.55% in 2021, and later surged by 5446.74% in 2025.
- Pliant Therapeutics' Income from Continuing Operations (Quarter) stood at -$24.5 million in 2021, then tumbled by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then surged by 47.11% to -$26.3 million in 2025.
- Its last three reported values are -$26.3 million in Q3 2025, -$43.3 million for Q2 2025, and -$56.2 million during Q1 2025.